Citigroup
SPRB

Citigroup’s Spruce Biosciences SPRB Stock Holding History

Citigroup’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.3K Buy
1,265
+326
+35% +$18.2K ﹤0.01% 4871
2026
Q1 		$61.4K Buy
+939
New +$64.8K ﹤0.01% 4446
2025
Q2 		– Sell
-148
Closed -$3.21K – 5972
2025
Q1 		$3.21K Buy
+148
New +$4.12K ﹤0.01% 5315
2022
Q3 		– Sell
-5
Closed -$1K – 6422
2022
Q2 		$1K Sell
5
-11
-69% -$1.41K ﹤0.01% 6119
2022
Q1 		$3K Sell
16
-13
-45% -$2.42K ﹤0.01% 6002
2021
Q4 		$10K Buy
29
+11
+61% +$3.27K ﹤0.01% 5570
2021
Q3 		$8K Buy
18
+12
+200% +$7.53K ﹤0.01% 5530
2021
Q2 		$5K Hold
6
– – ﹤0.01% 5856
2021
Q1 		$8K Sell
6
-11
-65% -$16.9K ﹤0.01% 5777
2020
Q4 		$31K Buy
+17
New +$28.2K ﹤0.01% 6381

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Citigroup's SPRB Position: Q2 2026 in Review

Citigroup increased its Spruce Biosciences (SPRB) stake by 35% in Q2 2026, buying an estimated $18.2K and bringing the position to 1,265 shares worth $68.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4871.

Citigroup first reported a position in SPRB in Q4 2020 and has held it in 10 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Citigroup held 1,265 shares of Spruce Biosciences worth $68.3K as of Q2 2026.
  • Citigroup bought 326 Spruce Biosciences shares in Q2 2026, an estimated $18.2K.
  • Spruce Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4871 holding.
  • Citigroup first reported a position in Spruce Biosciences in Q4 2020 and has held it in 10 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.